Avapritinib (BLU-285) is a small molecule kinase inhibitor that potently inhibits PDGFRα D842V mutant activity in vitro (IC50 = 0.5 nM) and PDGFRα D842V autophosphorylation in the cellular setting (IC50 = 30 nM); also a potent inhibitor of the analogous K
Avapritinib (BLU-285) is a small molecule kinase inhibitor that potently inhibitsPDGFRα D842Vmutant activity in vitro (IC50 = 0.5 nM) and PDGFRα D842V autophosphorylation in the cellular setting (IC50 = 30 nM); also a potent inhibitor of the analogousKit (c-Kit)mutation, D816V in Kit (c-Kit) Exon 17 (IC50 = 0.5 nM).
Targets
PDGFRα (D842V) ; c-Kit (D816V) 0.5 nM; 0.5 nM
In vitro
BLU-285 is a selective oral inhibitor that targets KIT Exon 17 and PDGFRα D842 activation loop mutants. Cellular assays measuring inhibition of KIT mutant autophosphorylation confirm the activity of BLU-285 against the KIT D816 mutants D816V (HMC1.2 cells, IC50 = 3 nM) and D816Y (P815 cells, IC50 = 22 nM) as well as other KIT Exon 17 mutants such as N822K (Kasumi cells, IC50 = 40 nM) found in treatment-refractory GIST.
In vivo
BLU-285 is a well-tolerated, orally bioavailable agent that achieves dose dependent tumor growth inhibition in a D816Y-driven xenograft model. A PK-PD-efficacy relationship with BLU-285 has been established demonstrating that tumor regression results from >90% target suppression and is observed with 30 mg/kg once daily dosing. With potent activity against PDGFRα D842V and KIT Exon 17 mutants, BLU-285 targets previously unaddressed genomic drivers of disease and provides promise for the treatment of PDGFRα D842V-driven GIST(gastrointestinal stromal tumor) or SM(systemic mastocytosis), where more than 90% of patients carry the KIT D816V mutation. Besides single agent activity, the highly selective BLU-285 offers an opportunity for combination with other agents in GIST to cover the entirety of KIT primary and resistance mutants.
1.Bai Y, Bandara G, Ching Chan E, Maric I, Simakova O, Bandara SN, Lu WP, Wise SC, Flynn DL, Metcalfe DD et al.. (2013) Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.. Leukemia, 27 (2):(278-85). [PMID:22907049][10.1021/op500134e]
2.Sanford M, McCormack PL. (2017) BLU-285, DCC-2618 Show Activity against GIST.. Cancer Discov, 7 (2):(121-122). [PMID:28077435][10.1021/op500134e]
3.Gotlib J. (2017) A molecular roadmap for midostaurin in mastocytosis.. Blood, 130 (2):(98-100). [PMID:28705853][10.1021/op500134e]
4.Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K et al.. (2017) A precision therapy against cancers driven by KIT/PDGFRA mutations.. Sci Transl Med, 9 (414):(1755-70). [PMID:29093181][10.1021/op500134e]
5.Sanford M, McCormack PL. (2018) Rapid Responses to Avapritinib (BLU-285) in Mastocytosis.. Cancer Discov, 8 (2):(133). [PMID:29233825][10.1021/op500134e]
6.Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, Vincenzi B. (2019) New frontiers in the medical management of gastrointestinal stromal tumours.. Ther Adv Med Oncol, 11 (13):(1755-70). [PMID:31205499][10.1177/1758835919841946]
7.Dhillon S. (2020) Avapritinib: First Approval.. Drugs, 80 (4):(433-439). [PMID:32100250][10.1021/op500134e]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
K2215211